证券日报网讯 2月26日，常山药业在互动平台回答投资者提问时表示，截至2026年2月13日，公司的股 东户数为45332户。 （文章来源：证券日报） ...

证券日报网讯 2月26日，常山药业在互动平台回答投资者提问时表示，二级市场股价波动受多种因素影 响，公司将持续努力提升经营质量，持续推进创新药审评工作，提升公司的内在价值。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 2月26日，常山药业在互动平台回答投资者提问时表示，公司正在开展依诺肝素钠注射液 在美国市场的销售相关工作，由于药品出口销售容易受到海外市场政策环境变化、销售渠道、汇率波 动、市场竞争等因素的影响，依诺肝素钠注射液未来在美国销售情况具有较大不确定性。股东协议转让 股份事项如有重大进展，公司将根据有关规则及时公告。阿贝那肽上市申请仍处于审评中，审评后续进 展请以公示信息为准。 ...

Group 1 - RuiLian New Materials reported a total operating revenue of 1.677 billion yuan for 2025, an increase of 14.95% year-on-year, with a net profit of 311 million yuan, up 23.48% year-on-year [1] - China Shenhua's subsidiary, Guoneng Qingyuan Power, successfully put its fourth generator unit into commercial operation, expected to provide approximately 20 billion kWh of clean energy annually [2] - Qijiang Airlines announced a 6.04% year-on-year decline in passenger turnover for January 2026, with a passenger load factor of 84.03%, up 1.61% year-on-year [3] Group 2 - QiZheng Tibetan Medicine reported a total operating revenue of 2.416 billion yuan for 2025, a year-on-year increase of 3.34%, with a net profit of 646 million yuan, up 10.98% year-on-year [5] - QiaoYin Co. announced the termination of its artificial intelligence industry headquarters project due to changes in investment cooperation conditions [6] - New Point Software plans to use 90.81 million yuan of surplus raised funds for new projects, including AI-driven software development [7] Group 3 - High Measurement Co. announced plans for major shareholders and executives to reduce their holdings by up to 3.19% of the company's shares [8] - SAIC Group's subsidiary plans to establish a private equity fund with an initial scale of 2.5 billion yuan, focusing on solid-state batteries and chip localization [9] - Tianqi Lithium announced the resignation of its deputy general manager due to personal career planning [10] Group 4 - ZhongKong Technology reported a total operating revenue of 8.051 billion yuan for 2025, a decrease of 11.90%, with a net profit of 450 million yuan, down 59.70% year-on-year [11] - Spring Airlines reported a 6.28% year-on-year increase in total passenger volume for January 2026, with a total available ton-kilometers of 57,008.37 [12] - Qifan Cable's controlling shareholder reduced its stake by 3% through various trading methods [13] Group 5 - China Chemical signed contracts worth a total of 36.925 billion yuan in January 2026, with significant contracts exceeding 5 billion yuan totaling 11.371 billion yuan [19] - SaiTuo Bio received a CEP certificate for its raw material drug Betamethasone, which is used to treat allergies and autoimmune inflammation [20] - Giant Star Agriculture reported a sales revenue of 649 million yuan from commodity fat pigs in January 2026, with a sales volume of 404,400 pigs [23] Group 6 - Qinglong Pipe Industry's subsidiary won a 146 million yuan pipeline project [24] - Changshan Pharmaceutical announced that some of its products are expected to be selected for national centralized procurement [26] - Yangdian Technology completed the transfer of 12.96% of its shares through an agreement [27] Group 7 - Deepin Technology's investment fund introduced new limited partners and adjusted the capital contributions of some partners [28] - Qingyun Technology plans to pledge 25% of its shares for a loan application of up to 30 million yuan [29] - LaiMei Pharmaceutical reported a 57.20% year-on-year decline in net profit for 2025 [30] Group 8 - YouLiDe reported a 16.88% year-on-year decline in net profit for 2025, with total operating revenue of 1.221 billion yuan, up 7.99% [31] - Warner Pharmaceutical reported a net profit of 241 million yuan for 2025, an increase of 46.95% year-on-year [32] - LianRui New Materials reported a net profit of 293 million yuan for 2025, an increase of 16.42% year-on-year [33] Group 9 - HuaQin Technology expects a 24.28% year-on-year decrease in net profit for 2025, with projected revenue of 1.251 billion yuan, up 9.83% [34] - QiPai Technology's shareholder subscribed for 6.3 million shares, accounting for 5.49% of the total share capital [35] - Qilin Security's shareholders completed their planned share reductions without exceeding the original plan [36] Group 10 - Dameng Data announced the lifting of the detention of its senior vice president, allowing him to resume his duties [37] - Haiyou Engineering won a contract for the "NFPS COMP5" project worth approximately 4 billion USD, with the company's share exceeding 800 million USD [38] - Yatai Group plans to sell 20.81% of its shares in Northeast Securities, pending confirmation of financial statements [39]

| 序号 | 拟中选药品名称 | 适应症 | | --- | --- | --- | | 1 | 那屈肝素(那曲肝素)注 射剂 | 那屈肝素钙注射液主要用于治疗静脉血栓形成中度或高度 | | | | 危险的情况，预防静脉血栓栓塞性疾病；治疗已形成的深静 | | | | 脉血栓；联合阿司匹林用于不稳定性心绞痛和非 Q 波性心肌 | | | | 梗死急性期的治疗；在血液透析中预防体外循环中的血凝块 | | | | 形成。 | | 2 | 依诺肝素注射剂 | 依诺肝素钠注射液用于预防静脉血栓栓塞性疾病（预防静脉 | | | | 内血栓形成），特别是与骨科或普外手术有关的血栓形成； | | | | 治疗已形成的深静脉栓塞，伴或不伴有肺栓塞，临床症状不 | | | | 严重，不包括需要外科手术或溶栓剂治疗的肺栓塞；与阿司 | | | | 匹林合用，治疗不稳定性心绞痛及非 波心肌梗死；用于血 Q | | | | 液透析体外循环中，防止血栓形成。 | 河北常山生化药业股份有限公司 关于公司参与国家组织集采药品协议期满品种接续采购 证券代码：300255 证券简称：常山药业 公告编号：2026-6 拟中选的公告 本公司及董事 ...

| 序号 | 拟中选药品名称 | 适应症 | | --- | --- | --- | | 1 | 那屈肝素(那曲肝素)注 | 那屈肝素钙注射液主要用于治疗静脉血栓形成中度或高度 | | | | 危险的情况,预防静脉血栓栓塞性疾病;治疗已形成的深静 | | | 射剂 | 脉血栓;联合阿司匹林用于不稳定性心绞痛和非Q波性心肌 | | | | 梗死急性期的治疗;在血液透析中预防体外循环中的血凝块 | | | | 形成。 | | 2 | 依诺肝素注射剂 | 依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉 | | | | 内血栓形成),特别是与骨科或普外手术有关的血栓形成; | | | | 治疗已形成的深静脉栓塞,伴或不伴有肺栓塞,临床症状不 | | | | 严重,不包括需要外科手术或溶栓剂治疗的肺栓塞:与阿司 | | | | 匹林合用,治疗不稳定性心绞痛及非○波心肌梗死;用于血 | | | | 液透析体外循环中,防止血栓形成。 | | | | 12 12 | 格隆汇2月13日丨常山药业(300255.SZ)公布，公司于近日参加了国家组织集采药品协议期满品种接续采购办公室（简称接续采购 办公室）组织的国家组织集采 ...

格隆汇2月13日丨常山药业(300255.SZ)公布，公司于近日参加了国家组织集采药品协议期满品种接续采购办公室（简称接续采购 办公室）组织的国家组织集采药品协议期满品种接续采购的投标工作（简称本次接续采购），根据接续采购办公室发布的《国家 组织集采药品协议期满品种接续采购拟中选结果公示》，公司部分药品拟中选本次接续采购。 | 序号 | 拟中选药品名称 | 适应症 | | --- | --- | --- | | 1 | 那屈肝素(那曲肝素)注 | 那屈肝素钙注射液主要用于治疗静脉血栓形成中度或高度 | | | | 危险的情况,预防静脉血栓栓塞性疾病;治疗已形成的深静 | | | 射剂 | 脉血栓;联合阿司匹林用于不稳定性心绞痛和非Q波性心肌 | | | | 梗死急性期的治疗;在血液透析中预防体外循环中的血凝块 | | | | 形成。 | | 2 | 依诺肝素注射剂 | 依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉 | | | | 内血栓形成),特别是与骨科或普外手术有关的血栓形成; | | | | 治疗已形成的深静脉栓塞,伴或不伴有肺栓塞,临床症状不 | | | | 严重,不包括需要外科手术或溶栓剂治 ...

经济观察网常山药业（300255）近期在业绩、监管、研发及公司行动等方面有多项动态值得关注。 业绩经营情况 公司依诺肝素钠注射液于2026年1月9日获美国FDA批准，用于预防静脉血栓栓塞性疾病。在研GLP-1类 药物艾本那肽注射液的2型糖尿病适应症上市申请已获受理，减重适应症临床试验于2025年6月获批，但 审评时间仍存不确定性。 公司结构与治理 2025年12月30日，公司公告拟吸收合并全资子公司梅山科技，以整合资源、降本增效，该事项已完成董 事会审议。此外，公司于2025年12月被调入深交所创业板指和创业板50指数样本股。 股票近期走势 近期股价呈现高位波动，2026年2月11日单日主力资金净流出4652.67万元，年内股价跌幅达24.64%。股 东户数截至2026年2月10日增至4.43万户，较上期增加2581户。 以上内容基于公开资料整理，不构成投资建议。 公司于2026年1月30日发布业绩预告，预计2025年归母净利润亏损1.9亿至2.85亿元，主要因肝素行业竞 争加剧、集采影响及毛利率承压。2025年年报预约于2026年4月25日披露。 监管情况 河北证监局于2026年2月5日通报，拟对常山药业信 ...

Group 1 - The main stocks with significant capital outflows include Xinyi Technology (-8.52 billion), Zhongji Xuchuang (-7.46 billion), and Shenghong Technology (-7.05 billion) [1] - Other notable stocks with capital outflows are Light Media (-6.74 billion), China Duty Free Group (-5.71 billion), and Zhongwen Online (-5.64 billion) [1] - Guizhou Moutai experienced a capital outflow of -5.61 billion, while Aerospace Electronics saw -5.46 billion [1] Group 2 - The stock performance shows that Xinyi Technology had a decline of -0.31%, and Zhongji Xuchuang decreased by -0.17% [2] - Light Media faced a significant drop of -10.8%, while Zhongwen Online fell by -6.91% [2] - Guizhou Moutai's stock decreased by -1.42%, and Aerospace Electronics dropped by -2.33% [2] Group 3 - Other companies with notable capital outflows include Agricultural Bank (-4.80 billion) and China Satellite (-4.79 billion) [3] - Industrial Fulian had a slight decline of -0.24%, while Xian Dao Intelligent saw a minimal change of -0.05% [3] - The overall trend indicates a significant capital outflow from various sectors, including telecommunications, media, and banking [1][2][3]

格隆汇2月11日丨常山药业(300255.SZ)在投资者互动平台表示，艾本那肽尚未完成审评。 ...